Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant leuprolide with or without docetaxel versus deferred therapy after radical prostatectomy in high-risk prostate cancer
2004-002203-32Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide and docetaxel in prostate cancer (PCa) (4 arms), sponsored by Sanofi. Primary endpoint: Progression-free survival after protocol-defined systemic therapy. Started Nov 2005; status: completed.
02
Drugs
leuprolidedocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-002203-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002203-32.